Genmab A/S (DKK)
GMAB
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range1606.00 | 1621.50
52-Wk Range |
Last Close-
Mkt Cap (m)-
Dividend yield-
ISINDK0010272202
Volume115,286
Exchange VenueCSE

Company Profile

Genmab A/S is a biotechnology company which creates and develops differentiated antibody therapeutics focused on the treatment of cancer. Its marketed product includes DARZALEX and Arzerra.

Key Information
Price/Earning-
Price/Book-
Price/Sales-
P/CF-
Rev Growth (3 year avg)38.73
EPS Growth (3 year avg)0.24
Operating Margin % 45.63
Net Margin %48.66
Return on Equity20.61
Debt/Equity-

Legal Documents

Prospectus
en 19/07/2019
Annual Report
en 31/12/2018

Financials

Income Statement
DKK201320142015201620172018
Revenue (m)6648501,1331,8162,3653,025
Operating Income (m)692657301,0531,3441,380
Net Income (m)1123017641,1871,1041,472
Basic EPS2.205.3513.0519.8318.1424.03
Avg. Diluted Shares Outstanding (m)525761626262
Balance Sheet
DKK201320142015201620172018
Current Assets (m)1,6932,7663,6684,8986,0597,433
Non Current Assets (m)391002353415441,028
Total Assets (m)1,7322,8673,9035,2386,6038,461
Current Liabilities (m)908656414412327443
Total Liabilities (m)------
Total Equity (m)6602,0333,4874,8276,2728,014
Cash Flows
DKK201320142015201620172018
Operating Cash Flows (m)-1281333113281,5891,015
Capital Expenditure (m)-10-75-135-33-89-477
Figures are quoted in DKK unless stated otherwise
1,615.00
Last Price